Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: BMS-982470; IL-21; Interleukin 21 - ZymoGenetics; rIL-21

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ZymoGenetics
  • Developer National Cancer Institute (Canada); ZymoGenetics
  • Class Antineoplastics; Interleukins
  • Mechanism of Action Immunostimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • No development reported Malignant melanoma; Non-Hodgkin's lymphoma; Renal cancer; Solid tumours
  • Discontinued Viral infections

Most Recent Events

  • 01 Dec 2014 Bristol-Myers Squibb completes a phase I trial for Solid tumours in USA (NCT01629758)
  • 01 Jun 2014 Bristol-Myers Squibb completes a phase I trial in Malignant melanoma (Combination therapy, Late stage disease) in USA and Puerto Rico (NCT01489059)
  • 01 Jul 2012 Phase-I clinical trials in Solid tumours (late-stage disease, combination therapy) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top